Suchergebnisse - "Li, Yinghong"

PubPharm (6)

1

Erratum : Author correction to 'Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects' [Acta Pharmaceutica Sinica B 13 (2023) 2138-2151

enthalten in: Acta pharmaceutica Sinica. B | 2024

von Wei, W. | Zeng, Q. | Wang, Y. | +13

ErratumFor: Acta Pharm Sin B. 2023 May;13(5):2138-2151. - PMID 37250154

2

Evolution and development of potent monobactam sulfonate candidate IMBZ18g as a dual inhibitor against MDR Gram-negative bacteria producing ESBLs

enthalten in: Acta pharmaceutica Sinica. B | 2023

von Li, Z. | Guo, Z. | Lu, X. | +14

3

Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects

enthalten in: Acta pharmaceutica Sinica. B | 2023

von Wei, W. | Zeng, Q. | Wang, Y. | +13

ErratumIn: Acta Pharm Sin B. 2024 Mar;14(3):1477. - PMID 38486984

4

Synthesis and biological evaluation of novel tricyclic matrinic derivatives as potential anti-filovirus agents

enthalten in: Acta pharmaceutica Sinica. B | 2018

von Zhang, X. | Liu, Q. | Li, Q. | +7

5

Synthesis and biological evaluation of 12-N-p-chlorobenzyl sophoridinol derivatives as a novel family of anticancer agents

enthalten in: Acta pharmaceutica Sinica. B | 2016

von Bi, C. | Ye, C. | Li, Y. | +3

6

Synthesis and biological evaluation of sophocarpinic acid derivatives as anti-HCV agents

enthalten in: Acta pharmaceutica Sinica. B | 2014

von Li, Y. | Peng, Z. | Gao, L. | +1

1
[1]